11 results about "Extracellular signal" patented technology

The invention relates to an antibody endocytosis efficiency detection method based on fluorescence resonance energy transfer, and belongs to the technical field of antibody endocytosis detection. The method comprises the following steps: coupling succinimide ester with an amino-containing compound to obtain a quenching agent, incubating an antibody to be detected and a target cell together, adding a fluorescence-labeled secondary antibody to carry out endocytosis reaction, removing an extracellular fluorescence signal by using the quenching agent after the reaction is finished, and detecting an intracellular fluorescence signal to obtain the endocytosis percentage of the antibody to be detected. The detection method provided by the invention is based on a fluorescence resonance energy transfer principle, an intracellular signal direct detection method in the prior art is optimized, and an extracellular fluorescence signal is removed, so that a detection system has higher sensitivity. The quenching agent provided by the invention can also be combined with an acid eluent in the prior art to further reduce an extracellular signal background value and improve the sensitivity of a detection system, can be applied to high-throughput detection of a to-be-detected antibody, is high in sensitivity and low in detection cost, and has a good application prospect.

The objective is to provide a novel method for improving the efficiency of osteogenic differentiation induction based on immobilized BMP-2. [Solution] A method for stimulating cells with ligand molecules, comprising a stimulation step of applying physical stimulation to the cells and / or ligand molecules, wherein the ligand molecule is bound to or interacts with a receptor protein expressed on the cells and is immobilized on a culture substrate and / or matrix molecule used for culturing the cells, the receptor protein mediates the transmission of extracellular signals to the cells based on its binding to the ligand molecule, and the extracellular signals are enhanced by the physical stimulation.

Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.

The present invention addresses the problem of providing a novel method for increasing bone differentiation induction efficiency based on immobilized BMP-2.　Provided is a method for stimulating a cell with a ligand molecule, the method including a stimulation step for applying a physical stimulus to the cell and / or the ligand molecule. The ligand molecule binds to or interacts with a receptor protein expressed on the cell, and is immobilized on a culture substrate and / or a matrix molecule used for culturing the cell. The receptor protein mediates the transmission of an extracellular signal to the cell on the basis of binding to the ligand molecule, and the extracellular signal is enhanced by the physical stimulus.

The invention relates to a method for preparing a therapeutic RNA platelet carrier. The method comprises at least the following steps: transducing at least one therapeutic RNA sequence together with at least one therapeutic RNA packaging sequence comprising an RNA binding protein sequence to a megakaryocyte progenitor cell and / or a hematopoietic stem and progenitor cell expressing CD34, using a DNA-based vehicle; the present invention relates to a therapeutic RNA sequence and / or packaging sequence encoding at least one therapeutic RNA product in a megakaryocyte (e.g., HSPC), an immature megakaryocyte, and / or a megakaryocyte; activating expression of the therapeutic RNA sequence and / or the therapeutic RNA packaging sequence; and generating platelets from a mature megakaryocyte derived from a transduced progenitor cell of the megakaryocyte and / or a transduced hematopoietic stem and progenitor cell (HSPC) expressing CD34 and / or a transduced immature megakaryocyte and / or a transduced megakaryocyte, wherein the expression activation step is regulated to occur during megakaryocyte maturation and / or platelet formation wherein the generated platelet carrier is functionally reactive to activation with a specific agonist wherein the generated platelet carrier is activated by an extracellular signal, and wherein the expression activation step is regulated to occur during megakaryocyte maturation and / or platelet formation. And wherein the platelet carrier produced contains the at least one therapeutic RNA product. The invention also relates to a therapeutic RNA platelet carrier engineered by the above method and its therapeutic use. In addition, the present invention relates to a pharmaceutical composition comprising an RNA platelet carrier engineered by the above method and therapeutic uses thereof.

The invention provides an activity-enhanced amniotic membrane matrix as well as a preparation method and application thereof. According to the invention, on the basis of amniotic cells, genes for coding IL-4 and IL-22 growth factors are introduced into the amniotic cells by using a gene editing technology, and the genes are secreted outside cell membranes by using extracellular signal peptides, so that the filling material containing high-activity biological factors is prepared, the cell proliferation, migration and tissue regeneration are remarkably promoted, and the biological factors have good biocompatibility. The wound healing and tissue repairing processes are accelerated.

Disclosed are a single-chain fragment variable (scFv) targeting KRAS G12V, a chimeric antigen receptor (CAR), and a use thereof. Based on the KRAS G12V target, a T cell receptor (TCR) is modified. An extracellular signaling domain of the TCR for recognizing a tumor-specific antigen (TSA) is retained and linked in series to an extracellular spacer, a transmembrane domain, and a CD3ζ-derived intracellular signaling domain in the conventional CAR structure, such that the modified CAR can specifically recognize a KRAS G12V mutant polypeptide presented by HLA-A*02:01. Moreover, based on the advantages of CAR-T cell / NK cell therapy, potential new tumor treatment options are explored to lay a foundation for clinical trials.

The present invention relates to the technical field of tumor immunotherapy. Provided are a dual-targeting chimeric antigen receptor, a gene encoding same, a recombinant expression vector, a natural killer cell, and the use. The dual-targeting chimeric antigen receptor comprises a dual CAR molecule encoding sequence, which consists of the following sequentially linked sequences: an extracellular antigen-binding domain encoding sequence, a transmembrane domain encoding sequence, and an intracellular signal transduction domain encoding sequence. The extracellular domain of a PD1 molecule serves as a first recognition target, and the extracellular domain of an NKG2D molecule serves as a second recognition target. When the extracellular signal domain of PD1 recognizes a PD-L1 molecule on a tumor cell, the activation of the DAP10 activating receptor pathway is triggered by downstream transduction of a negative regulatory signal, thereby converting the negative regulatory signal into a positive activating signal. Meanwhile, when the extracellular domain of the NKG2D molecule recognizes an NKG2DLs molecule on the tumor cell, the NK cell can also be activated, and under the synergistic action of co-stimulatory molecules 41BB and CD3 zeta, the antitumor treatment effect of the NK cell is greatly enhanced.

The application discloses application of 1-aminocyclopropane carboxylic acid in preparation of a glioma treatment drug. The 1-aminocyclopropane carboxylic acid of the application not only significantly inhibits the expression level of glial fibrillary acidic protein of glioma cells, but also effectively inhibits the expression and phosphorylation modification of extracellular signal-regulated kinase 1 / 2 and protein kinase B, blocks the cell proliferation signal mediated by the MAPK / ERK and PI3K / Akt / mTOR signal pathways, and activates the cell apoptosis signal mediated by caspase 3, so that the proliferation of glioma cells is inhibited, the growth speed of a xenograft of a nude mouse is effectively slowed down, the volume and mass of tumor tissues are significantly reduced, and a significant therapeutic effect is achieved.

The invention discloses an intracellular electric signal non-invasive reconstruction method and system based on an artificial neural network, and the method comprises the steps: obtaining an extracellular signal, inputting the preprocessed extracellular signal into a trained artificial neural network, and predicting to obtain an intracellular electric signal; the artificial neural network comprises a convolutional neural network and a long-short-term memory network, and the artificial neural network is trained by the following method: acquiring an extracellular sample signal and a paired intracellular sample signal, classifying the extracellular sample signal and the intracellular sample signal, taking the extracellular sample signals and the intracellular sample signals meeting preset classification requirements as a sample set; and training a preset model according to the preprocessed sample set, updating parameters of the preset model according to a preset loss function until preset requirements are met, and obtaining a trained artificial neural network. The embodiment of the invention can stably record the action potential signal in the cell for a long time in a non-invasive manner, and can be widely applied to the technical field of signal detection.

Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.